Castle Biosciences (CSTL) Cash & Equivalents (2018 - 2026)

Castle Biosciences has disclosed Cash & Equivalents across 9 years of filings, most recently posting $62.1 million for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 24.46% year-over-year to $62.1 million; the TTM figure through Jun 2026 stood at $62.1 million (down 24.46% YoY), while the FY2025 annual figure was $116.7 million, down 2.49% from the prior year.
• Cash & Equivalents came in at $62.1 million for Q2 2026 at Castle Biosciences, down from $63.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $309.0 million in Q1 2022 to a low of $62.1 million in Q2 2026.
• Average Cash & Equivalents over 5 years is $118.0 million, with a median of $95.4 million recorded in 2023.
• Year-over-year, Cash & Equivalents plunged 64.89% in 2023 and climbed 21.11% in 2024.
• Over 5 years, Cash & Equivalents stood at $122.9 million in 2022, then slipped by 19.61% to $98.8 million in 2023, then gained by 21.11% to $119.7 million in 2024, then retreated by 2.49% to $116.7 million in 2025, then sank by 46.79% to $62.1 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $62.1 million in Q2 2026, $63.8 million in Q1 2026, and $116.7 million in Q4 2025.